Carna Biosciences, Inc. reported consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company's net sales were JPY 169,964,000 against JPY 211,132,000 a year ago. Operating loss was JPY 233,119,000 against JPY 188,874,000 a year ago. Loss was JPY 236,814,000 against JPY 194,481,000 a year ago. Basic loss per share was JPY 23.16 against JPY 20.36 a year ago.

For full year ending December 31, 2019, the consolidated company expects net sales of JPY 1,240 million, operating loss of JPY 1,658 million, loss attributable to owners of parent of JPY 1,693 million or JPY 166.03 per share.